Further hematological studies revealed marked reticulocytopenia in all treated shRNA Rpl5 mice (n=3) (reticulocytes 1.77%, 0.1x106/ul) versus controlmice (n=3) (reticulocytes 3.8%, 0.24x106/ul) and bone marrow erythroblastopenia (myeloid to erythroid linage 4.9 in all shRNA Rpl5 mice and 3.4 in control mice). This evidence concerns the gene RPL5 and Reticulocytopenia.